Comparative Preclinical Pharmacokinetics and Disposition of Favipiravir Following Pulmonary and Oral Administration as Potential Adjunct Therapy Against Airborne RNA Viruses
Pharmaceutical Research · 2024
DOI: 10.1007/s11095-024-03782-3 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pharmaceutical Research, 2024. Verfasst von Venkata Siva Reddy Devireddy und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Sector 10A, Janakipuram Extension, Sitapur Road, Lucknow, 22603…. Hauptthemen laut MEDLINE: Pyrazines, Amides, Antiviral Agents, Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: CSIR-Central Drug Research Institute.
Abstract (Originalsprache)
BACKGROUND: Favipiravir is administered orally, even against airborne RNA viruses, in a loading-dose/maintenance dose regimen. We investigated whether-(a) pulmonary delivery of favipiravir would generate high concentrations in the luminal side of the respiratory tract; and (b) avoiding first-pass metabolism by the liver by inhaled drug would generate comparable pharmacokinetics (PK) with doses significantly smaller than the oral maintenance dose. METHODS: A dry powder inhalation (DPI) of favipiravir formulated by mixing with Inhalac 400® was prepared and characterized. Inhalations of ~ 120 µg dose strength, with or without a prior oral loading dose were administered to mice. Comparator mice received human-equivalent oral doses (3 mg). Three mice per sampling time point were sacrificed and favipiravir concentrations in the blood plasma, bronchio-alveolar lavage fluid (BALF) and lung tissue homogenate determined by HPLC. RESULTS: One-compartment PK modeling of concentration-time data indicated that the area under the curve (AUC0-24 h) generated in the BALF recovered from mice receiving inhalations of ~ 1/25th of the oral dose subsequent to an oral loading dose was 86.72 ± 4.48 µg⋅mL-1⋅h. This was consistently higher than the AUC observed in the BALF of orally-dosed mice (56.71 ± 53.89 µg mL-1⋅h). In blood serum, the respective values of AUC were 321.55 ± 124.91 and 354.71 ± 99.60 µg⋅mL-1⋅h. CONCLUSION: Pulmonary delivery of significantly smaller doses of favipiravir generates meaningful drug disposition and pharmacokinetics at the site of respiratory viral infections. We provide the rationale for designing a self-administered, non-invasive, low-cost, targeted drug delivery system against airborne RNA virus infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Sector 10A, Janakipuram Extension, Sitapur Road, Lucknow, 226031, India.
- Academy of Scientific and Innovative Research (AcSIR), Sector 19, Kamla Nehru Nagar, Ghaziabad, 201002, India.
- Institute of Nano Science and Technology, Sector 81, Sahibzada Ajit Singh Nagar, 140306, India.
- Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Sector 10A, Janakipuram Extension, Sitapur Road, Lucknow, 226031, India. amit_misra@cdri.res.in.
- Academy of Scientific and Innovative Research (AcSIR), Sector 19, Kamla Nehru Nagar, Ghaziabad, 201002, India. amit_misra@cdri.res.in.
Förderung
- CSIR-Central Drug Research Institute
Zitieren
APA
Devireddy, V. S. R., Shafi, H., Verma, S., Singh, S., Chakradhar, J. V. U. S., Kothuri, N., Bansode, H., Raman, S. K., Sharma, D., Azmi, L., Verma, R. K., & Misra, A. (2024). Comparative Preclinical Pharmacokinetics and Disposition of Favipiravir Following Pulmonary and Oral Administration as Potential Adjunct Therapy Against Airborne RNA Viruses. Pharmaceutical Research. https://doi.org/10.1007/s11095-024-03782-3
Vancouver
Devireddy VSR, Shafi H, Verma S, Singh S, Chakradhar JVUS, Kothuri N, et al. Comparative Preclinical Pharmacokinetics and Disposition of Favipiravir Following Pulmonary and Oral Administration as Potential Adjunct Therapy Against Airborne RNA Viruses. Pharmaceutical Research. 2024. doi:10.1007/s11095-024-03782-3
BibTeX
@article{Devireddy2024,
author = {Devireddy, Venkata Siva Reddy and Shafi, Hasham and Verma, Sonia and Singh, Sanjay and Chakradhar, J V U S and Kothuri, Naresh and Bansode, Himanshu and Raman, Sunil Kumar and Sharma, Deepak and Azmi, Lubna and Verma, Rahul Kumar and Misra, Amit},
title = {Comparative Preclinical Pharmacokinetics and Disposition of Favipiravir Following Pulmonary and Oral Administration as Potential Adjunct Therapy Against Airborne RNA Viruses},
journal = {Pharmaceutical Research},
year = {2024},
doi = {10.1007/s11095-024-03782-3}
}
EUVIMED